Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy
- 1 April 1982
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3) , 179-180
- https://doi.org/10.1007/bf00254544
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group BCancer, 1980
- Podophyllotoxin derivative VP 16-213Cancer Chemotherapy and Pharmacology, 1979
- Chemotherapy of small cell carcinoma of the lung with V. P. 16–213Cancer, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- PHASE-2 CLINICAL-TRIAL WEEKLY ADMINISTRATION OF VP-16-213 IN SMALL CELL BRONCHOGENIC CARCINOMA1977
- VP-16-213 VERSUS POLYCHEMOTHERAPY IN PATIENTS WITH ADVANCED SMALL CELL LUNG-CANCER1976